The criteria of choice of proton pump inhibitor at acid-dependent diseases such as gastroesophageal reflux, peptic ulcer, diseases associated with Helicobacter pylory are discussed in the article. The presented data of meta-analysis of efficiency (clinical-and-endoscopic, economical), safety and tolerance, cost and simplicity of use show that today rabeprasol (pariet) is the drug of choice.